Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for chronic urticaria.

Riccardo Asero1, Alberto Tedeschi

  • 1Ambulatorio di Allergologia, Allergy Unit, Clinica San Carlo, Via Ospedale 2120037 Paderno Dugnano (MI), Italy. r.asero@libero.it

Expert Opinion on Emerging Drugs
|April 26, 2006
PubMed
Summary

Chronic urticaria (CU) involves autoimmune factors and may be linked to the clotting cascade. Research suggests coagulation system drugs could be a new treatment for this persistent skin condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge of chronic spontaneous urticaria management among Italian general practitioners: Baseline findings from the BRIDGE study.

The World Allergy Organization journal·2026
Same author

D-Dimer Elevation in Spontaneous Urticaria and Bullous Pemphigoid, Two Chronic Inflammatory Skin Diseases.

American journal of hematology·2026
Same author

IgE to cyclophilin Bet v 7 triggers mast cell activation and mediates cross-reactivity with Ara h 18 in children with seasonal allergic rhinitis.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

BRIDGE implementation science study to improve chronic spontaneous urticaria outcomes in Italy.

The journal of allergy and clinical immunology. Global·2026
Same author

Diagnostic Delay in Patients With Chronic Urticaria: Results From the Chronic Urticaria Registry (CURE).

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry.

Allergy·2026

Area of Science:

  • Dermatology
  • Immunology
  • Hematology

Background:

  • Chronic urticaria (CU) is a common condition characterized by itchy wheals lasting over six weeks.
  • Autoimmune factors are implicated in up to 50% of CU cases.
  • Current treatments include antihistamines, corticosteroids, and immunosuppressants, with limited options for severe, refractory cases.

Purpose of the Study:

  • To investigate the potential role of the coagulation system in the pathogenesis of chronic urticaria.
  • To explore novel therapeutic targets for chronic urticaria based on emerging pathogenetic insights.

Main Methods:

  • Review of recent findings on autologous plasma skin tests in CU patients.
  • Analysis of plasma markers of thrombin activation (prothrombin fragment F(1.2)) in CU.
  • Re-evaluation of existing studies on anticoagulation therapies in CU.

Main Results:

  • Autologous plasma skin tests are frequently positive in CU patients.
  • Elevated levels of prothrombin fragment F(1.2) indicate thrombin activation in CU plasmas, regardless of autoimmune or idiopathic origin.
  • These findings suggest a potential involvement of the clotting cascade in CU pathogenesis.

Conclusions:

  • The coagulation system may play a significant role in the development of chronic urticaria.
  • Further investigation into heparin and oral anticoagulants as potential treatments for CU is warranted.
  • This research opens new avenues for understanding and managing chronic urticaria.

Related Experiment Videos